Our Science – Rixe Website

Olivier Rixe, M.D., Ph.D.

Medical Oncology Branch and Affiliates Staff Clinician National Cancer Institute Building 10 - Magnuson CC, Room 13N240 10 Center Dr ive, MSC 1903 Bethesda, MD 20892 Phone:   301-435-2279 Fax:   Fax Number not listed E-Mail:   rixeo@mail.nih.gov

Biography

Olivier Rixe, MD, PhD, received his medical degree from the Pierre and Marie Curie University, Paris, France, followed by a training in medical oncology and internal medicine which he completed at University of Paris in 1988. He spent one year in 1991 in the NCI's Medicine Branch under the direction of Dr Tito Fojo. Following his stay at the NCI, Dr Rixe received his PhD in Molecular Biology from Diderot University in Paris. He then served as a senior medical oncologist in Gustave-Roussy Institute, Villejuif, France and was appointed Professor of medical oncology in 2004 in Pierre and Marie Curie University. Dr Rixe joined the NCI in February 2008 as a full time physician in the Medical Oncology Branch.

Research

Dr Rixe's main interest in cancer research has focused on (1) Preclinical research studying the problem of drug resistance; (2) Investigations evaluating the feasibility of gene therapy as an anti-cancer therapy; and (3) Clinical research with the goal of evaluating and developing new anticancer agents for all cancers, with a focus recently on renal cell carcinoma.
Active in numerous drug trials, Dr. Rixe has been involved in the development of such agents as oxaliplatin, camptothecins, and taxanes, as well as targeted therapies including the antiangiogenic compounds sunitinib, axitinib and VEGF-trap.

Dr Rixe's clinical trials interest focus on two major areas: the treatment of kidney cancer and early drug development.
Complementing his research endeavors, Dr. Rixe has authored or co-authored more than 100 scientific articles.
Dr. Rixe is a member of several professional organizations, including the American Society of Clinical Oncology, American Association for Cancer Research, and European Society for Medical Oncology. For the past three years, he has served as Chairman of the French Kidney Cancer Specialized Program of Research Excellence (SPORE) .

This page was last updated on 8/4/2008.